Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV002000136 | SCV002230142 | pathogenic | not provided | 2021-05-07 | criteria provided, single submitter | clinical testing | This sequence change creates a premature translational stop signal (p.Arg232*) in the ASXL3 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in ASXL3 are known to be pathogenic (PMID: 26647312, 28100473). This variant is not present in population databases (ExAC no frequency). This variant has not been reported in the literature in individuals with ASXL3-related conditions. For these reasons, this variant has been classified as Pathogenic. |
Prevention |
RCV004728986 | SCV005336492 | likely pathogenic | ASXL3-related disorder | 2024-05-18 | no assertion criteria provided | clinical testing | The ASXL3 c.694C>T variant is predicted to result in premature protein termination (p.Arg232*). To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.00091% of alleles in individuals of European (Non-Finnish) descent in gnomAD. Nonsense variants in ASXL3 are expected to be pathogenic. This variant is interpreted as likely pathogenic. |